Advertisement

Tumor Biology

, Volume 35, Issue 11, pp 10891–10896 | Cite as

RETRACTED ARTICLE: Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13

  • Yinghai Ye
  • Xiaocong Zhou
  • Xiaoyang Li
  • Yinhe Tang
  • Yusheng Sun
  • Jun Fang
Research Article

Abstract

The molecular pathway regulating gastric carcinoma (GC) invasiveness and metastasis remains elusive. Here, we detected significant increase in the phosphorylated epidermal growth factor receptor (pEGFR), MMP7, and MMP13 in the resected GC, compared with the adjacent normal tissue, in patients. Moreover, strong positive correlation was detected between pEGFR and MMP7, and between pEGFR and MMP13 in GC. To examine whether a causal link exists, we used two human GC lines, SNU-5 and AGS, to study the cross talk between EGFR signaling activation, and expression of MMP7 and MMP13. We found that EGF-induced EGFR phosphorylation activated both MMP7 and MMP13, and consequently cancer invasiveness. EGF-induced activation of MMP7 and MMP13 can be both inhibited by use of an inhibitor for EGFR. EGF-induced activation of MMP7 can be also significantly inhibited by use of an inhibitor for Akt, but not an inhibitor for ERK1/2, while EGF-induced activation of MMP13 can be significantly inhibited by use of an inhibitor for ERK1/2, but not by an inhibitor for Akt. These data suggest that EGF-induced activation of MMP7 and MMP13 in GC is through phosphatidylinositol 3-kinase (PI3K) and extracellular-related kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway, respectively. Our study thus highlights EGFR signaling regulated MMP7 and MMP13 activation as molecular basis for metastasis of GC, and further demonstrate that different signaling pathway cascades are involved in the downstream signaling transduction.

Keywords

Gastric cancer Epidermal growth factor receptor PI3K Akt ERK/MAPK MMP7 MMP13 

Notes

Conflicts of interest

None.

References

  1. 1.
    Zhao X, Li X, Yuan H. Micrornas in gastric cancer invasion and metastasis. Front Biosci. 2013;18:803–10.CrossRefGoogle Scholar
  2. 2.
    Cardoso AP, Pinto ML, Pinto AT, Oliveira MI, Pinto MT, Goncalves R, et al. Macrophages stimulate gastric and colorectal cancer invasion through egfr y(1086), c-src, erk1/2 and akt phosphorylation and smallgtpase activity. Oncogene. 2014;33:2123–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (egfr) expression and mutational phenotype. Gastric Cancer : official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2012;15:252–64.CrossRefGoogle Scholar
  4. 4.
    Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of egfr and her2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2008;272:296–306.CrossRefPubMedGoogle Scholar
  5. 5.
    Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Cho S, et al. Egf-induced mmp-9 expression is mediated by the jak3/erk pathway, but not by the jak3/stat-3 pathway in a skbr3 breast cancer cell line. Cell Signal. 2009;21:892–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 2009;218:460–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Whelan JT, Hollis SE, Cha DS, Asch AS, Lee MH. Post-transcriptional regulation of the ras-erk/mapk signaling pathway. J Cell Physiol. 2012;227:1235–41.CrossRefPubMedGoogle Scholar
  8. 8.
    McKay MM, Morrison DK. Integrating signals from rtks to erk/mapk. Oncogene. 2007;26:3113–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Li Z, Zhang D, Zhang H, Miao Z, Tang Y, Sun G, et al. Prediction of peritoneal recurrence by the mRNA level of cea and mmp-7 in peritoneal lavage of gastric cancer patients. Tumour Biol. 2014;35:3463–70.CrossRefPubMedGoogle Scholar
  10. 10.
    Shi M, Liu D, Duan H, Han C, Wei B, Qian L, et al. Catecholamine up-regulates mmp-7 expression by activating ap-1 and stat3 in gastric cancer. Mol Cancer. 2010;9:269.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagstrom J, et al. Mmp-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010;31:149–55.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhao C, Bu X, Zhang N, Wang W. Downregulation of sfrp5 expression and its inverse correlation with those of mmp-7 and mt1-mmp in gastric cancer. BMC Cancer. 2009;9:224.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (mmp-13) in human malignant tumors. APMIS. 1999;107:45–53.CrossRefPubMedGoogle Scholar
  14. 14.
    Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, et al. Mir-34a regulates cisplatin-induce gastric cancer cell death by modulating pi3k/akt/survivin pathway. Tumour Biol. 2014;35:1287–95.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang JL, Chen GW, Liu YC, Wang PY, Wang X, Wan YL, et al. Secreted protein acidic and rich in cysteine (sparc) suppresses angiogenesis by down-regulating the expression of vegf and mmp-7 in gastric cancer. PLoS One. 2012;7:e44618.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yonemura Y, Endou Y, Fujita H, Fushida S, Bandou E, Taniguchi K, et al. Role of mmp-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer J Int Gastric Cancer Assoc Japan Gastric Cancer Assoc. 2000;3:63–70.Google Scholar
  17. 17.
    del Casar Lizcano JM, Vizoso Pineiro F, Gonzalez Sanchez LO, Martin Suarez A, Gava R, Cuesta Fernandez E. Diez Santisteban MC: [expression and clinical significance of collagenase-3 (mmp-13) in gastric cancer]. Gastroenterol Hepatol. 2003;26:1–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (vegf) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35–52.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636–46.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the hif system. Nat Med. 2003;9:677–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yinghai Ye
    • 1
  • Xiaocong Zhou
    • 1
  • Xiaoyang Li
    • 1
  • Yinhe Tang
    • 2
  • Yusheng Sun
    • 3
  • Jun Fang
    • 3
  1. 1.Department of SurgeryWenzhou Central HospitalWenzhouChina
  2. 2.Department of Hepatobiliary SurgeryThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina
  3. 3.Department of Trauma SurgeryThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina

Personalised recommendations